Matches in Wikidata for { <http://www.wikidata.org/entity/Q92217034> ?p ?o ?g. }
Showing items 1 to 45 of
45
with 100 items per page.
- Q92217034 description "article scientifique publié en 2019" @default.
- Q92217034 description "artículu científicu espublizáu n'avientu de 2019" @default.
- Q92217034 description "im Dezember 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92217034 description "scientific article published on 22 December 2019" @default.
- Q92217034 description "wetenschappelijk artikel" @default.
- Q92217034 description "наукова стаття, опублікована 22 грудня 2019" @default.
- Q92217034 name "Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer" @default.
- Q92217034 name "Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer" @default.
- Q92217034 type Item @default.
- Q92217034 label "Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer" @default.
- Q92217034 label "Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer" @default.
- Q92217034 prefLabel "Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer" @default.
- Q92217034 prefLabel "Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer" @default.
- Q92217034 P1433 Q92217034-5936D794-9994-490F-A6D6-D475DBBE9B12 @default.
- Q92217034 P1476 Q92217034-6EFF87C3-C062-47A3-8835-310C7B1FBAF6 @default.
- Q92217034 P2093 Q92217034-05410715-601C-4E0A-AAD0-94AE58E140B3 @default.
- Q92217034 P2093 Q92217034-87B3A5D1-A4AF-4514-98D9-D7A27495EE0E @default.
- Q92217034 P2093 Q92217034-A247DC0C-E502-40AB-9514-89B13EF8941A @default.
- Q92217034 P2093 Q92217034-BA64FFCB-0211-4C52-97EB-3C9F8DA6AA24 @default.
- Q92217034 P31 Q92217034-47BBA332-23C4-420D-B914-1E19A7C511DC @default.
- Q92217034 P356 Q92217034-59EFAEBD-9042-41D2-BA63-F483988A1258 @default.
- Q92217034 P50 Q92217034-1A58D306-C71C-4A9D-9036-FD6B30BAEC68 @default.
- Q92217034 P50 Q92217034-4991CF92-A7F6-4E22-B8B4-1911C7F93C4A @default.
- Q92217034 P50 Q92217034-8B4A98DA-1AE1-4591-B9CB-BD054829EA5B @default.
- Q92217034 P577 Q92217034-1F552155-BB36-492F-B404-33CB08AF32DC @default.
- Q92217034 P698 Q92217034-298CD867-7109-4C79-B60B-A9B6348909DE @default.
- Q92217034 P921 Q92217034-78571B63-7F04-431D-B883-1FB2FD01FDA7 @default.
- Q92217034 P932 Q92217034-E0097E95-EDFF-4FA6-92A2-F872F7D6A91A @default.
- Q92217034 P356 IJGC-2019-001012 @default.
- Q92217034 P698 31871115 @default.
- Q92217034 P1433 Q15749181 @default.
- Q92217034 P1476 "Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer" @default.
- Q92217034 P2093 "Heather Lankes" @default.
- Q92217034 P2093 "Jyoti Mayadev" @default.
- Q92217034 P2093 "Russell Schilder" @default.
- Q92217034 P2093 "Wei Deng" @default.
- Q92217034 P31 Q13442814 @default.
- Q92217034 P356 "10.1136/IJGC-2019-001012" @default.
- Q92217034 P50 Q88394112 @default.
- Q92217034 P50 Q90697657 @default.
- Q92217034 P50 Q91946596 @default.
- Q92217034 P577 "2019-12-22T00:00:00Z" @default.
- Q92217034 P698 "31871115" @default.
- Q92217034 P921 Q160105 @default.
- Q92217034 P932 "7310564" @default.